Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Lucinda (Lucy) Griffiths

BSc Econ (Hons.)

Senior Trial Development Manager

  • Oncology Clinical Trial Office (OCTO)

Lucy's experience within clinical trial management spans almost 16 years (13 of those working with CTIMPs), during which she has gained a comprehensive range of experience, skills and in-depth knowledge and understanding of ICH-GCP, trial methodology, clinical research structures and management, applicable regulatory and ethical systems, and the importance of working to these.

Lucy joined the Department of Oncology in June 2011 as a Clinical Trial Administrator in the Oncology Clinical Trial Office (OCTO) before shortly becoming a Trial Manager. In September 2022 Lucy was promoted to work as the Senior Trial Development Manager (STDM) for OCTO, which has since included focussing on clinical trial development for several cancer vaccines and CTIMP based oncology trials, as well as trials with prevention and early detection aims.

The STDM’s role is to work with Chief Investigators and collaborators to oversee all pre-award trial activity associated with the development of new University of Oxford sponsored oncology clinical trial projects, which included protocol development, interfacing with local governance and contract negotiation groups; engagement with local chief investigators; and coordination with academic laboratories and research facilities. The role also includes working closely with the Oxford Cancer team to identify and support opportunities for new trial collaborations.

Before working in OCTO, Lucy worked as a Study Coordinator of over-the-counter medicines and health products clinical trials, for a commercial contract research organisation, which involved running multi-centre studies on-site directly with participants in the UK and in China.

OCTO Trials currently or previously involved with:


EMERALD - Pancreas - Evaluation of hypofractionated adaptive radiotherapy using the MR Linac in localised pancreatic cancer

LUD2015-005 - Phase 1/2 Study of anti-PD-L1 in Combination with Chemo(radio)therapy for Oesophageal Cancer

NUTIDE-301 - A two-part, Phase 1 open-label dose escalation and expansion study to assess safety, pharmacokinetics and clinical activity of NUC-3373, a nucleotide analogue, in participants with advanced solid tumours. 

PEMBLAPembrolizumab in intermediate risk recurrent non-muscle invasive bladder cancer (NMIBC)

TARDOX - A Proof of Concept Study to Investigate the Feasibility of Targeted Release of Doxorubicin from Lyso-thermosensitive Liposomal (LTSL) Doxorubicin (ThermoDox®) Using Focused Ultrasound in Patients with Primary or Secondary Liver Tumours

6MP - A phase II clinical trial of 6-mercaptopurine (6MP) and methotrexate in patients with BRCA defective tumours

CHOP-OR -A study of ofatumumab with CHOP chemotherapy for Richter's syndrome (CHOP-OR)

SONATINA - A Phase II Multi-Centre Randomised Controlled Study Of Nelfinavir Addition to Radiotherapy Treatment In Neo-Adjuvant Therapy for Rectal Cancer